Remedy Plan Therapeutics
PrivateLast Round
VC Round
May 13, 2025
Total Funding Raised
$22.91M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Remedy Plan Therapeutics is a biotechnology company developing a pipeline of novel, hyperbolic NAMPT inhibitors to treat a range of diseases including solid tumors, hematologic malignancies, obesity, and autoimmune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Remedy Plan Therapeutics Comparables
Compare Remedy Plan Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoTartis, Inc. | 90% | |
| Dracen Pharmaceuticals, Inc. | 77% | |
| Valerio Therapeutics | 74% | |
Remedy Plan Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 13, 2025 | ||||
| Series A | Aug 1, 2023 | ||||
| Early Funding | Nov 20, 2018 | ||||
| Grant | Sep 20, 2018 | ||||
| Crowdfunding | Nov 6, 2015 |
Key People
Founding team and executive leadership
Remedy Plan Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Alexandria Venture Investments | VC Round |
| Schooner Capital | VC Round, Early Funding |
| Maryland Tech Council | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 8, 2026
Jotin Marango appointed as Chief Financial and Business Officer.
- Jan 1, 2026
Presented multiple times at the AACR Annual Meeting 2026.
Remedy Plan Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Remedy Plan Therapeutics's valuation, stock price, and market status.